A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT07008118 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Neoplasms

Interventions

DRUG: INCA035784

Sponsor

Incyte Corporation